quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:05·116d
SECFiling
Verrica Pharmaceuticals Inc. logo

SEC Form EFFECT filed by Verrica Pharmaceuticals Inc.

VRCA· Verrica Pharmaceuticals Inc.
Health Care
Original source

Companies

  • VRCA
    Verrica Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Nov 6UpdateH.C. Wainwright-
  • Nov 5UpdateRBC Capital Mkts-
  • Jul 25UpdateNeedham$10.00
  • Mar 22UpdateJefferies$10.00
  • Feb 13UpdateRBC Capital Mkts$11.00
  • May 25UpdateRBC Capital Mkts$4.00

Related

  • SEC3d
    SEC Form DEFA14A filed by Verrica Pharmaceuticals Inc.
  • SEC3d
    SEC Form DEF 14A filed by Verrica Pharmaceuticals Inc.
  • PR14d
    Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
  • PR17d
    Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
  • SEC43d
    SEC Form 10-K filed by Verrica Pharmaceuticals Inc.
  • SEC43d
    Verrica Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
  • PR43d
    Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
  • PR49d
    Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022